Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China

Study identifier:D1790C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Two Cohort, Open label, Single and Multiple Dose Pharmacokinetic Study of 4mg/Kg and 6mg/Kg Doses of Daptomycin in Healthy Chinese Subjects Living in China

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Daptomycin

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Feb 2009

Primary Completion Date: -

Study Completion Date: 01 Mar 2009

Study design

Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Beijing, China

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1210&filename=CSR-D1790C00002.pdf
Download
CSR-D1790C00002.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

1-800-236-933

information.center@astrazeneca.com

Investigators

Principal Investigator

Gang Chen

AZ Pharmaceuticals - China